| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFITM1 |
| Uniprot No | P13164 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-125aa |
| 氨基酸序列 | MHKEEHEVAVLGAPPSTILPRSTVINIHSETSVPDHVVWSLFNTLFLNWC CLGFIAFAYSVKSRDRKMVGDVTGAQAYASTAKCLNIWALILGILMTIGF ILLLVFGSVTVYHIMLQIIQEKRGY |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFITM1重组蛋白的3篇参考文献摘要：
1. **"IFITM1重组蛋白的制备及其抗病毒活性研究"**(作者：李明等)
摘要：通过原核表达系统成功制备重组IFITM1蛋白，验证其在体外抑制流感病毒H1N1入侵宿主细胞的能力，揭示了IFITM1通过膜融合干扰机制发挥抗病毒作用。
2. **"Structural characterization of recombinant human IFITM1 by X-ray crystallography"**(作者：Smith A, et al.)
摘要：首次解析了重组人源IFITM1蛋白的晶体结构，发现其独特的跨膜螺旋构象，为解释IFITM家族蛋白抑制包膜病毒进入的分子机制提供了结构基础。
3. **"Recombinant IFITM1 modulates TLR3 signaling and attenuates herpes simplex virus infection"**(作者：Chen X, et al.)
摘要：研究重组IFITM1蛋白对TLR3通路的调控作用，证明其通过增强干扰素信号通路抑制单纯疱疹病毒(HSV-1)复制，提示其潜在免疫调节功能。
注：以上文献名为示例性概括，实际文献需通过PubMed/Google Scholar以关键词“IFITM1 recombinant”检索获取。
Interferon-induced transmembrane protein 1 (IFITM1) is a member of the IFITM family, which plays critical roles in innate immunity, particularly in restricting viral infections. Encoded by an interferon-stimulated gene (ISG), IFITM1 is upregulated in response to interferons (IFNs) during viral or bacterial challenges. It is a small, single-pass transmembrane protein localized to endolysosomal and plasma membranes, where it disrupts viral entry by altering membrane fluidity or trapping viral particles in intracellular compartments. IFITM1 is notably effective against enveloped viruses, including influenza, dengue, Zika, and coronaviruses, though its activity varies across pathogens.
Recombinant IFITM1 protein is engineered using expression systems like *E. coli* or mammalian cells to study its structure, antiviral mechanisms, and interactions. Its production enables detailed biochemical analyses, such as mapping domains responsible for membrane curvature modulation or viral restriction. Recombinant forms are also used to develop therapeutic strategies, such as enhancing cellular antiviral defenses or designing peptide mimics. However, challenges persist in maintaining its native conformation post-purification due to its transmembrane nature and lipid-dependent functionality.
Beyond virology, IFITM1 is implicated in cancer, where it exhibits dual roles—either suppressing metastasis by inhibiting cell migration or promoting tumor growth via immune evasion. Recombinant IFITM1 aids in deciphering these context-dependent effects, offering insights into tissue-specific signaling pathways. Despite progress, unresolved questions remain about its regulation, post-translational modifications, and species-specific antiviral spectra. Ongoing research leverages recombinant IFITM1 to address these gaps, bridging fundamental biology with translational applications in infectious diseases and oncology.
×
